Extravasation and emigration of neutrophils to the site of inflammation are essential early steps in the initiation of many antibody-mediated autoimmune diseases. The Fc domains of cell bound autoantibodies or immune-complexes (IC) are capable of triggering the neutrophil emigration via complement and FcγRs-mediated mechanisms. To define the clinical relevance and the relative contribution of these 2 pathways in IC-mediated neutrophil emigration, we have neutralized the FcγR-binding activity of IC with a recombinant dimeric Fc receptor, CD16A-Ig, and investigated the early events of IC-induced inflammation in mice. Systemic administration of purified CD16A-Ig blocked IC-induced inflammation, mast- cell degranulation, and extravasation of neutrophils in a reversed Arthus reaction. Although the binding of CD16A-Ig to IC did not alter the complement-activating properties of IC, no evidence for complement-dependent neutrophil emigration was observed. These results suggest that interaction of IC with cells expressing FcγRs at the inflammatory site results in the secretion of chemoattractants, which mediate complement-independent emigration of neutrophils in this cutaneous acute inflammation model. Furthermore, blocking the interaction of IC to FcγRs expressed on inflammatory cells by administering high-avidity Fc fusion dimers of low-affinity FcγRs is an effective way of preventing IC-induced acute inflammation in autoimmune diseases.

Autoimmune diseases are heterogeneous in nature and are the most frequent cause of disability in adults.1  Many autoimmune diseases lead to vital organ damage, disability and are often fatal in humans. Both the cellular and humoral arms of the immune system are involved in the pathogenesis of autoimmune diseases. Abnormal activation of autoantigen specific T and B cells due to molecular mimicry, viral infections, or cytokine dysregulation are among the suggested mechanisms for the initiation of the disease.2  In many autoimmune diseases the binding of autoantibodies to tissues causes tissue injury. The effector functions of the Fc domains of these tissue-antigen bound antibodies depend on their ability to interact with complement components and/or Fc gamma receptors (FcγRs) expressed on inflammatory cells. The relative role and contribution of these 2 effector systems to the initiation and development of antibody mediated inflammatory diseases are still under intense investigation

Studies have shown that the accumulation of neutrophils at the site of IC deposition is pivotal to the development of antibody-mediated autoimmune inflammation.3  The ICs trigger complement activation and production of chemotactic peptides such as C5a, which directly attract neutrophils to the inflammatory site.4,5  Apart from attracting neutrophils, C5a also induce degranulation of mast cells resulting in further recruitment of neutrophils to the site of IC deposition.5,7  These studies were further supported by the fact that mice deficient in C5a receptor gene show attenuated autoantibody-induced inflammation.4,8  Thus the complement peptides produced by IC orchestrate accumulation of neutrophils and cause tissue damage. On the other hand, studies using Fcγ knockout mice have demonstrated the pivotal role of FcγRs in neutrophil recruitment9,10  and antibody-mediated autoimmune diseases. The Fcγ subunit is essential for cell-surface expression of activating FcγRs such as CD64, FcγRIV, and CD16A.11,,14  These Fcγ or CD16A gene knockout mice did not develop autoimmune diseases under experimental conditions that induced the diseases in wild type mice.15,,18 

Although these knockout mice studies have demonstrated independent roles of complement and FcγRs, recent observations suggest interdependency of these 2 pathways in the progression of inflammation.19  At the inflammatory site, C5a increases the potency of the FcγR-dependent inflammatory pathway by up-regulating activating CD16A while down-regulating inhibitory CD32B in inflammatory cells.20  Furthermore, the interaction of IC with CD16A upregulates the production of cell-derived C5.21  This suggests that the absence of the complement pathway might influence the effectiveness of the FcγR-mediated pathway of inflammation and vice versa. Because many of these studies used either gene knockout mice or mast cell deficient mice which might have adapted developmental compensatory mechanisms, the results and interpretations of the relative role of these functionally interdependent pathways may or may not reflect normal conditions. Therefore, to further understand the IC-induced inflammatory pathways leading to neutrophil emigration in mice with intact complement system and FcγRs, we analyzed acute inflammation induced by IC after administration of novel decoy FcγR dimers. The dimeric CD16A-Ig fusion protein we used22,23  does not block complement activation by IC, but maintains its potential to competitively block the interaction of ICs with FcγR-expressing inflammatory cells. Our data demonstrate that the interaction of IC with FcγR-expressing cells, present at the extravascular site, is critical for the production of complement-independent chemoattractants that trigger the extravasation and emigration of neutrophils during the early phase of the cutaneous Arthus reaction.

Cell lines and reagents

The ovalbumin-fluorescein isothiocyanate (FITC-Ova) and rabbit antiovalbumin IgG were from Roche Molecular Biochemicals (Indianapolis, IN). PKH-26 labeling kit, mouse IgG subtypes, rabbit anti-DNP IgG, HRP-conjugated anti–human Fc antibody, cobra venom factor, and pepsin were from Sigma (St Louis, MO). Rabbit anti-DNP IgG-Alexa-fluro-448 was from Molecular Probes/Invitrogen (Carlsbad, CA). The Micro BCA-protein assay kit was from Pierce (Rockford, IL) and the horseradish peroxidase (HRP)-substrate from BioRad (Hercules, CA). FITC-conjugated F(ab′)2-goat anti–mouse IgG and HRP-conjugated F(ab′)2 goat anti–mouse IgG were from Jackson Immunoresearch Laboratories (West Grove, PA). The Rat-on-Mouse polymer detection kit was from Biocare Medicals (Concord, CA). 2.4G2, an anti–mouse CD16A/CD32B mAb, was from BD Pharmingen. F(ab′)2 of 2.4G2 was generated as described.24  F4/80, rat-anti–mouse macrophage antibody, was from AbD Serotec (Oxford, United Kingdom). The mouse macrophage cell line P388D1 was from the American Type Culture Collection (Manassas, VA). Cell culture reagents were from Life Technologies (Gaithersburg, MD). C57BL/6 (8- to 10-week-old) female mice were from Jackson laboratory (Bar Harbor, Maine). The experiments with mice were conducted following Emory University institutional animal care and use committee protocol. Macrophages were obtained from the peritoneal cavity of C57BL/6 mice 2 days after injecting 2 mL of 3% thioglycollate broth and were purified by adherence of the cells to tissue culture plates for 2 hours at 37°C. Cells were used within 4 days for the experiments.

Construction, expression, and purification of recombinant soluble CD16A-Ig and CD32A-Ig

The construction and expression of the dimeric form of CD16A-Ig by ligating the extracellular domain of human CD16A to the Fc domain of the human IgG1 heavy chain has already reported by us.22  The Fc domain has mutations that abolish the FcγR-binding activity of IgG1 molecules.25,27  A similar strategy was used to construct and express the R-allele of human CD32A-Ig. The recombinant molecules were purified from CHO cell transfectants using a protein-G GammaBind Plus (Pharmacia Biotech, Piscataway, NJ) Sepharose column. The purified CD16A-Ig and CD32A-Ig were analyzed using 10% sodium dodecyl sulfate–polyacrylamise gel electrophoresis (SDS-PAGE) under reducing and nonreducing conditions, and the protein bands were visualized by silver staining and Western blot. Protein concentration was measured using the Micro BCA protein assay kit (Pierce) with BSA as a standard.

Soluble IC binding assay

Soluble immune complex (sIC) was prepared by mixing FITC-Ova with rabbit anti-Ova IgG (1:1 molar ratio) for 4 hours at 4°C.28,29  The complex was centrifuged at 355g for 30 minutes at 4°C and the supernatant was used for the FITC-IC binding assay. The macrophages (50 μl of 5 × 106) were preincubated with blocking agents for 30 minutes at 4°C and then incubated with FITC-IC (20 μg/mL) in binding buffer (pH 7.4) for 1 hour at 4°C. The cells were then washed and analyzed by flow cytometry.

EA binding and phagocytosis assays

Analysis of rabbit anti-DNP IgG–opsonized sheep erythrocytes (EA) binding to macrophages was carried out by flow cytometry as described earlier28,29  after labeling EA with PKH fluorescent dye. Briefly, sheep red blood cells (SRBC) were coated with DNP as described30  and opsonised with rabbit anti-DNP IgG. The phagocytosis assay was carried out using flow cytometry as described by Zhang et al31  using sheep erythrocytes with Alexa-flura-448–labeled rabbit anti-DNP antibodies (Alexa-EA) at a ratio of 1:50 (macrophages to Alexa-EA) in the presence or absence of 2.4G2 or CD16A-Ig.

Complement-mediated hemolytic assay

Complement-mediated hemolytic activity of mouse serum was carried out as described.32  Briefly, rabbit red blood cells (rRBCs) were opsonized with rabbit anti-DNP-IgG as described for SRBCs (“EA binding and phagocytosis assay”). The IgG-opsonized rRBCs (100 μL of 2 × 108 cells/mL) in dextrose-gelatin vernal (DGV) buffer were incubated with or without various concentrations of CD16A-Ig for 1 hour at 4°C, after which 100 μl of 1:5 diluted mouse serum was added and the samples incubated at 37°C for 60 minutes. The reaction was stopped by the addition of 0.8 mL of ice-cold DGV buffer. All the samples were centrifuged for 5 minutes at 700g at 4°C. The supernatant was collected and read at 450 nm.

In vivo FcγR-Ig clearance studies

The mice were injected with 100 μg/mouse of dimers intravenously. Subsequently, 3 μl of blood samples were collected at several time points and diluted to 300 μL in phosphate-buffered saline (PBS)/5mM EDTA (ethylene diamino tetra acetic acid) and plasma was separated by centrifugation. A sandwich enzyme-linked immunosorbent assay (ELISA) was carried out to detect the presence of dimers in the plasma using FcγR-specific mAbs as capture antibodies and HRP-conjugated anti–human Fc–specific antibody as the detection antibody.

Reversed passive Arthus reaction (RPA)

RPA was carried out as described.18  To determine the effect of locally administered CD16A-Ig, mice were injected intradermally in the dorsal skin with 25 μL of PBS (control), 20 μg of anti-ovalbumin rabbit IgG (anti-Ova), or various concentrations of CD16A-Ig or CD32A-Ig mixed with 20 μg anti-Ova at defined sites.

To determine the effect of systemically administered CD16A-Ig, CD16A-Ig was administered intravenously to the mice (n = 3) at concentrations of 5, 25, and 50 μg/mL of blood. The blood volume in milliliters was estimated to be 7% of mouse body weight in grams.33  After 1 hour, mice were injected with 12.5 or 25 μg per site of anti-Ova intradermally in a total volume of 25 μL of PBS at different sites. At 5 minutes after injection of anti-Ova, RPA was initiated by injecting 100 μL PBS containing 500 μg of ovalbumin and 1% Evan blue through the tail vein. The mice were killed after 3 hours and the injection sites on the reverse side of the skin were examined for extravasation of the blue dye. Photographs were taken immediately and used to quantitate the degree of inflammation elicited by RPA reaction. The intensity of each dermal lesion, shown in blue in the photographs, was quantified using ImageJ software (National Institutes of Health, Bethesda) and KaleidaGraph (Synergy Software, Reading, PA). After the photographs, skin biopsies taken from injection areas were subjected to histologic analysis. The skin biopsies were sliced horizontally, fixed in 4% buffered formalin, embedded in paraffin, and stained with hematoxylin and eosin. Immunohistochemistry of paraffin-embedded tissue was performed to detect the accumulation of macrophage using rat anti–mouse F4/80 antibody. The antibodies were detected using Rat-on-Mouse polymer detection kit.

In some experiments, hypocomplementemia was induced by injecting the mice twice intraperitoneally with 150 U cobra venom factor (CVF) at 8-hour intervals beginning 24 hours before the initiation of RPA reaction.18  The complement-depleting activity of CVF was determined by assaying the hemolysis of rRBC by mouse serum as described.32 

Microscopes and image acquisition

Images shown in Figures 2A and 3A were taken using digital Sony cyber-shot DSC-P200, 7.2 mega pixel camera (Sony Style, Atlanta, GA). Images shown in Figures 4A,C, and 5A,C were acquired using a Nikon Eclipse 80i microscope with 40×/0.95 DICM/N2 objectives. Neutrophils and macrophages were counted in the slides at 10 random sites using 63×/1.4 DIC N2 objectives (Nikon Instruments, Melville, NY). Mast cell degranulation (Figure 4 insets) images were acquired using Olympus BX40F microscope (Olympus, Melville, NY) with 100×/1.4 NA objectives and photographs were taken with a digital Nikon-D100 6.1 mega pixel camera. All the photos were saved as JPEG files. Images were processed using Microsoft Photo Editor software (Microsoft, Redmond, WA).

Statistical analysis

A statistical comparison of the control and treated samples was performed using student t test; P less than .01 (*) considered as significant and P less than .001 (**) considered as highly significant.

The human CD16A-Ig dimer blocks IC binding and phagocytosis by mouse macrophage FcγRs

Previously, we reported that purified human CD16A-Ig was able to compete with cell surface expressed human FcγRs for binding to ICs.22  It is known that human FcγRs are known to bind IgG from other species, such as mouse and rabbit. However, before administering human dimeric CD16A-Ig and CD32A-Ig in mice, we assessed whether the purified dimeric molecules could block IC binding functions of mouse FcγRs in vitro. We used the mouse macrophage cell line P388D1, which expresses all 3 types of FcγRs: CD16A, CD32B, and CD64. Coincubation of the P388D1 cells with CD16A-Ig blocked the binding of the soluble IC (sIC) in a dose dependent manner (Figure 1A). At 25 μg/mL, CD16A-Ig blocked up to 70% of sIC binding. The combination of CD16A-Ig and mIgG2a was able to block up to 80%, whereas mIgG2a alone blocked only 20% of sIC binding (Figure 1B). Because monomeric mIgG2a binds specifically to CD64,34  the results suggest that CD64 contributes minimally to IC binding by macrophages in our system. This is not due to lack of CD64 functional activity. Flow cytometry analysis showed that the macrophage cell line that we used binds to free IgG2a (Figure S1A, available on the Blood website; see the Supplemental Materials link at the top of the online article), suggesting that either some or all of the CD64 is functionally available to bind IgG. The results obtained using the F(ab′)2 fragment of 2.4G2, which specifically blocks CD16A/CD32B molecules, also demonstrate that 80% of the IC binding is mediated by CD16A/CD32B-dependent mechanisms (Figure S1B). At present we do not know the reason for the low IC binding activity of CD64. It is possible that the high affinity CD64 molecule may be partially occupied by IgG from the serum used for culturing cells or has lower affinity for rabbit IgG. The combination of CD16A-Ig and CD32A-Ig blocked up to 70% of sIC binding, which is not more effective than CD16A-Ig alone; suggesting that CD32A-Ig is not an efficient blocker of mouse FcγRs in vitro. This is further supported by the minimal blockage observed with CD32A-Ig (Figure 1B). Some IC, such as autoantibody-coated target cells, are particulate in nature and therefore we assessed whether the soluble dimeric receptors can block the binding of particulate IC (antibody-coated sheep erythrocytes; EA) to mouse macrophage cells. Nearly 70% of EA binding to P388D1 was blocked by CD16A-Ig at 25 μg/mL, whereas CD32A-Ig was unable to block EA binding (Figure 1C). Results obtained using mIgG2a and mAb specific to CD16A/CD32B showed that CD64 plays little or no role in the EA binding (Figure 1C), which is consistent with the results from the sIC-binding studies described above (Figure 1B). CD16A-Ig also blocked EA binding to macrophages isolated from mouse peritoneal cavity in a dose dependent fashion (Figure S2A). At 25 μg/mL, CD16A-Ig was able to block up to 70% of EA binding, whereas CD32A-Ig was unable to block at the doses tested (Figure S2B). Phagocytosis of antibody-coated target cells by macrophages and neutrophils is one of the major mechanisms by which autoantibodies lead to tissue injury in many acute and chronic inflammatory autoimmune diseases. Therefore, we determined whether CD16A-Ig could block phagocytosis mediated by FcγRs expressed on mouse macrophages. Flow cytometric analysis of phagocytosed Alexa-EA showed that pretreatment of EA with 50 μg/mL of CD16A-Ig blocked up to 60% of the EA phagocytosis by the P388D1 cells (Figure 1D). A similar result was observed using primary cells such as the thioglycollate-elicited peritoneal macrophages (Figure S2C). Taken together, this data demonstrates that dimeric CD16A-Ig is capable of competing with FcγRs expressed on mouse inflammatory cells for binding to IC.

Figure 1

CD16A-Ig competes with cell surface FcγRs and blocks immune-complex binding and phagocytosis by mouse macrophage cells. (A) CD16A-Ig blocked the binding of soluble IC to the mouse macrophage cell line P388D1 in a dose dependent manner. P388D1 cells were incubated with FITC-IC (soluble IC) in the presence and absence of various concentrations of CD16A-Ig and the cells were analyzed for binding of FITC-IC using flow cytometry. (B) Specificity of blocking by CD16A-Ig. P388D1 cells were incubated with soluble IC in the presence of the following reagents: anti-CD16A/32B mAb (2.4G2), CD16A-Ig and CD32A-Ig or mIgG2a. The FITC-IC binding to P388D1 cells was analyzed using standard flow cytometry. (C) CD16A-Ig blocked the binding of particulate IC to the mouse macrophage cells. P388D1 cells (50 μl of 5 × 106/mL) in binding buffer (PBS/5 mM EDTA/1% BSA) were incubated with PKH labeled EA (50 μL of 1.5 × 108) for 2 hours at 4°C. Binding assays were performed in the absence or presence of CD16A-Ig or CD32A-Ig, or 10 μg/mL blocking mAbs for mouse CD16A/CD32B. Monomeric mIgG2a (50 μg/mL) was used to block CD64. Blocking mAbs (2.4G2), CD16A-Ig, and CD32A-Ig were preincubated for 30 minutes at 4°C and then continuously present during their incubation with EA. EA bound to the cells were analyzed by flow cytometry. Cells incubated with PKH-labeled unopsonized-E were used as a background control. The EA binding in presence of medium was taken as 100% to calculate the percentage EA binding. Data shown are the average (mean ± SD) of 3 individual experiments. (D) CD16A-Ig blocked the phagocytosis of opsonized cells by macrophages. Phagocytosis of Alexa-EA was carried out using P388D1 cells. P388D1 cells were incubated with Alexa-EA in the absence or presence of the following blocking reagents: 2.4G2 (10 μg/mL) and CD16A-Ig (25, 50, and 75 μg/mL). The cells were then fixed and the fluorescence of phagocytosed Alexa-EA was measured using flow cytometry. Cells incubated with EA at 4°C served as the background control. The phagocytic index (PI) was calculated using the formula PI = %P × MF/100.59  The experiment was repeated twice. Data shown are the average of 3 individual experiments. *P < .01, **P < .001.

Figure 1

CD16A-Ig competes with cell surface FcγRs and blocks immune-complex binding and phagocytosis by mouse macrophage cells. (A) CD16A-Ig blocked the binding of soluble IC to the mouse macrophage cell line P388D1 in a dose dependent manner. P388D1 cells were incubated with FITC-IC (soluble IC) in the presence and absence of various concentrations of CD16A-Ig and the cells were analyzed for binding of FITC-IC using flow cytometry. (B) Specificity of blocking by CD16A-Ig. P388D1 cells were incubated with soluble IC in the presence of the following reagents: anti-CD16A/32B mAb (2.4G2), CD16A-Ig and CD32A-Ig or mIgG2a. The FITC-IC binding to P388D1 cells was analyzed using standard flow cytometry. (C) CD16A-Ig blocked the binding of particulate IC to the mouse macrophage cells. P388D1 cells (50 μl of 5 × 106/mL) in binding buffer (PBS/5 mM EDTA/1% BSA) were incubated with PKH labeled EA (50 μL of 1.5 × 108) for 2 hours at 4°C. Binding assays were performed in the absence or presence of CD16A-Ig or CD32A-Ig, or 10 μg/mL blocking mAbs for mouse CD16A/CD32B. Monomeric mIgG2a (50 μg/mL) was used to block CD64. Blocking mAbs (2.4G2), CD16A-Ig, and CD32A-Ig were preincubated for 30 minutes at 4°C and then continuously present during their incubation with EA. EA bound to the cells were analyzed by flow cytometry. Cells incubated with PKH-labeled unopsonized-E were used as a background control. The EA binding in presence of medium was taken as 100% to calculate the percentage EA binding. Data shown are the average (mean ± SD) of 3 individual experiments. (D) CD16A-Ig blocked the phagocytosis of opsonized cells by macrophages. Phagocytosis of Alexa-EA was carried out using P388D1 cells. P388D1 cells were incubated with Alexa-EA in the absence or presence of the following blocking reagents: 2.4G2 (10 μg/mL) and CD16A-Ig (25, 50, and 75 μg/mL). The cells were then fixed and the fluorescence of phagocytosed Alexa-EA was measured using flow cytometry. Cells incubated with EA at 4°C served as the background control. The phagocytic index (PI) was calculated using the formula PI = %P × MF/100.59  The experiment was repeated twice. Data shown are the average of 3 individual experiments. *P < .01, **P < .001.

Close modal

CD16A-Ig inhibits antibody-mediated acute inflammation in vivo in a murine reversed passive Arthus reaction (RPA) model

Next, we determined whether the in vivo administration of purified CD16A-Ig dimer could block the antibody mediated acute inflammation induced in a murine RPA model.35  RPA has been extensively studied as an in vivo model of immune complex-mediated acute tissue injury and inflammation. The reaction is induced by injecting an antigen (chicken ovalbumin; Ova) intravenously along with a blue dye followed by intradermal administration of polyclonal antibodies (rabbit antiovalbumin IgG; anti-Ova) specific to the antigen. Vascular permeability and extravasation of neutrophils, a hallmark of the IC-induced immunopathologic cascade, can be visualized by extravasation of intravenously injected Evan blue dye and standard histologic analysis.

First, we determined the optimal concentration of anti-Ova required to induce inflammation by injecting various concentrations of anti-Ova (0-50 μg/site) intradermally. We found that Arthus reaction was induced optimally with 20 μg/site of rabbit anti-Ova (data not shown). We then determined the ability of locally administered CD16A-Ig and CD32A-Ig to inhibit the induction of RPA. The results show that the administration of CD16A-Ig at the site of IC-formation significantly (P < .001) decreased the size and intensity of the inflammation compared with the sites injected with rabbit anti-Ova alone (Figure 2A left panels). The degree of inflammation was not reduced at CD32A-Ig injected sites, suggesting that CD32A-Ig is unable to block IC binding to mouse FcγRs in vivo.

Figure 2

Local administration of CD16A-Ig at the inflammatory site blocked reversed passive Arthus reaction in mice with or without complement depletion. (A) The mice (n = 3) were injected intradermally with PBS (site 1), or various concentrations of CD16A-Ig (0 μg/mL at site 2, 5 μg/mL at site 3, 25 μg/mL at site 4, and 50 μg/mL at site 5) along with rabbit anti-Ova antibody in PBS, immediately after which ovalbumin with 1% Evan blue was injected through the tail vein. To deplete the complement, mice were twice injected intraperitoneally with cobra venom factor before the initiation of RPA. After 3h the mice were euthanized, and the dorsal side of the skin was photographed for analysis. The figure shows 3 representative mice. (B) Quantitative analysis of RPA. The dermal lesion, seen blue in the photographs, was quantified using ImageJ and KaleidaGraph softwares for groups with or without CVF treatment. Data are presented as mean plus or minus the SD from 3 individual mice. *P < .01, **P < .001.

Figure 2

Local administration of CD16A-Ig at the inflammatory site blocked reversed passive Arthus reaction in mice with or without complement depletion. (A) The mice (n = 3) were injected intradermally with PBS (site 1), or various concentrations of CD16A-Ig (0 μg/mL at site 2, 5 μg/mL at site 3, 25 μg/mL at site 4, and 50 μg/mL at site 5) along with rabbit anti-Ova antibody in PBS, immediately after which ovalbumin with 1% Evan blue was injected through the tail vein. To deplete the complement, mice were twice injected intraperitoneally with cobra venom factor before the initiation of RPA. After 3h the mice were euthanized, and the dorsal side of the skin was photographed for analysis. The figure shows 3 representative mice. (B) Quantitative analysis of RPA. The dermal lesion, seen blue in the photographs, was quantified using ImageJ and KaleidaGraph softwares for groups with or without CVF treatment. Data are presented as mean plus or minus the SD from 3 individual mice. *P < .01, **P < .001.

Close modal

The IC-mediated Arthus reaction may be triggered by either of two pathways: the complement system and the FcγRs.18,36,,,40  To determine the contribution of complement-mediated RPA in our system, hypocomplementemia was induced in mice using cobra venom factor (CVF) as described by Hazenbos et al.18  The depletion of complement was confirmed by estimating the hemolytic activity of the serum obtained from CVF-treated mice and normal mice (Figure S3). We then studied the effectiveness of CD16A-Ig and CD32A-Ig administration in inhibiting the RPA. No decrease in the intensity of RPA was observed in complement-depleted mice (Figure 2A right panels). CD16A-Ig blocked RPA in a dose dependent manner (Figure 2B). At 50 μg/mL it was able to block up to 70% of RPA, whereas CD32A-Ig had no detectable effect under similar condi-tions (Figure 2B). Moreover, the combination of CD16A-Ig and CD32A-Ig was able to block only 70% of RPA, which is not more effective than CD16A-Ig alone; suggesting that CD32A-Ig is not competing with murine FcγRs in vivo (data not shown).

We then determined the efficacy of these dimers in blocking the IC-mediated inflammation when administered systemically. As observed with locally administered CD16A-Ig, the systemically administered CD16A-Ig also blocked RPA in a dose dependent manner (Figure 3Aiv-vi). A dose of 50 μg/mL of blood CD16A-Ig blocks more than 70% of the inflammation as measured by the intensity of the Evan blue extravasation (Figure 3B). Under similar conditions, as seen in the previous experiments (Figure 2), CD32A-Ig was unable to block RPA (Figure 3B), demonstrating the specificity of the inhibition of RPA by CD16A-Ig. Similar experiments with systemically administered molecules conducted in CVF-treated mice showed that complement depletion did not have any effect on the intensity of RPA (data not shown). These data show that systemic administration of recombinant soluble dimeric CD16A-Ig effectively blocks the IC-mediated inflammation in vivo.

Figure 3

Systemic administration of CD16A-Ig efficiently blocked the reversed passive Arthus reaction in vivo in mice without complement depletion. (A) The mice (n = 3) were injected with various concentrations of CD16A-Ig intravenously (panel iv, 5 μg/mL; panel v, 25 μg/mL; panel vi, 50 μg/mL of blood). After 1 hour, mice were injected intradermally with PBS (site 1), 12.5 μg (site 2), and 25 μg (site 3) of anti-Ova per site. RPA was initiated by injecting Ova with 1% Evan blue intravenously through tail vein. For CD32A-Ig, 50 μg of CD32A-Ig/mL of blood was injected (panel ii). The antibody (2.4G2) treated control mice (panel iii) were injected with 25 μg/mL of blood (40 μg/mice) mAb. The PBS-injected mice served as the untreated positive control (panel i). After 3 hours the mice were killed, and the dorsal side of the skin was photographed for analysis. The figure shows 3 representative mice. (B) Quantitative analysis of RPA. The dermal lesion, shown in blue in the photographs, was quantified using ImageJ and KaleidaGraph softwares for groups with or without FcγR dimer treatment. Data are presented as the mean plus or minus the SD from 3 experiments. *P < .01, **P < .001.

Figure 3

Systemic administration of CD16A-Ig efficiently blocked the reversed passive Arthus reaction in vivo in mice without complement depletion. (A) The mice (n = 3) were injected with various concentrations of CD16A-Ig intravenously (panel iv, 5 μg/mL; panel v, 25 μg/mL; panel vi, 50 μg/mL of blood). After 1 hour, mice were injected intradermally with PBS (site 1), 12.5 μg (site 2), and 25 μg (site 3) of anti-Ova per site. RPA was initiated by injecting Ova with 1% Evan blue intravenously through tail vein. For CD32A-Ig, 50 μg of CD32A-Ig/mL of blood was injected (panel ii). The antibody (2.4G2) treated control mice (panel iii) were injected with 25 μg/mL of blood (40 μg/mice) mAb. The PBS-injected mice served as the untreated positive control (panel i). After 3 hours the mice were killed, and the dorsal side of the skin was photographed for analysis. The figure shows 3 representative mice. (B) Quantitative analysis of RPA. The dermal lesion, shown in blue in the photographs, was quantified using ImageJ and KaleidaGraph softwares for groups with or without FcγR dimer treatment. Data are presented as the mean plus or minus the SD from 3 experiments. *P < .01, **P < .001.

Close modal

As specificity controls for RPA, groups (n = 3) of mice were injected intradermally at different sites with either PBS or PBS containing various concentrations of anti-Ova antibody or FcγR dimers, and immediately 100 μl of 1% Evan blue in PBS intravenously. These control experiments show that the intradermally injected FcγR-Ig dimers or anti-Ova do not cause inflammation per se (data not shown). We have also determined the effect of systemically administered anti–mouse CD16A mAb on the RPA. The results show that IC-induced RPA can be effectively blocked by anti-CD16A/CD32B mAb (Figure 3B); demonstrating IC-induced inflammation in our experiments is mediated by FcγRs.

Histologic analyses show that CD16A-Ig blocks IC-induced accumulation of inflammatory cells and tissue damage mediated by mouse FcγRs

To visualize the intensity and character of the inflammation in RPA, the skin biopsies taken from antibody-injected areas of untreated, CD16A-Ig–treated and CD32A-Ig–treated mice, shown in Figure 3A, were subjected to histologic analysis. As a control, a PBS-injected area of untreated mice was used. Tissue sections from the anti-Ova injected area of untreated mice revealed edema and an inflammatory infiltrate composed predominantly of neutrophils as characterized by their multilobed nuclei (Figure 4Ai,B) and degranulated mast cell (Figure 4Ai top inset). Histologic sections of anti-Ova–injected areas of skin taken from the mice treated with CD16A-Ig showed a marked reduction in neutrophil accumulation, margination around venules (Figure 4Aiii,B), and degranulation of mast cells (Figure 4Aiii top inset) compared with the untreated mice (Figure 4Ai), whereas the skin sections of CD32A-Ig–treated mice (Figure 4Aiv) showed features that were similar to those observed in untreated mice (Figure 4Ai). PBS-injected area of untreated mice did not show any evidence of inflammation (Figure 4Aii).

Figure 4

Histologic examination and evaluation of neutrophil infiltration in skin biopsies from anti-Ova injected areas of mice treated with or without FcγR dimers. (Ai) Skin biopsy from anti-Ova antibody–injected area in an untreated mouse with RPA (from Figure 3Ai site 3). The epidermis and dermis are essentially unremarkable. However, the subdermal fat is edematous and shows the margination of neutrophils along capillary walls (arrows; bottom inset) as well as neutrophilic infiltration into surrounding soft tissue. (Aii) Skin biopsy from PBS-injected area in an untreated mouse with RPA (from Figure 3Ai site 1). No specific pathologic changes are identified. (Aiii) Skin biopsy from anti-Ova antibody injected area in a mouse treated with 50 μg/mL CD16A-Ig before the induction of RPA (from Figure 3Avii site 3). No specific pathologic changes are identified, suggesting abrogation of the Arthus reaction. (Aiv) Skin biopsy from anti-Ova antibody injected area in a mouse treated with 50 μg/mL CD32A-Ig before the induction of RPA (from Figure 3Aii site 3). The epidermis and dermis are essentially unremarkable. However, the subdermal fat is edematous and shows neutrophilic infiltrates in soft tissue (similar to Figure 3Ai), as well as scattered foci of leukocytoclastic vasculitis (arrows; bottom inset). Top inset: Mast cell degranulation was observed in 10 different sites at 100x magnification and one of the cells is represented in the figure inset. (B) Neutrophils were counted in 10 random sites at 63x magnification and sum of the neutrophils were represented. C: To deplete the complement, mice were twice injected intraperitoneally with cobra venom factor before the initiation of RPA. The mice were injected with CD16A-Ig and CD32A-Ig intravenously (50 μg/mL of blood). After 1 hour, mice were injected intradermally with 25 μg of anti-Ova per site. (Ci) Skin biopsy from anti-Ova antibody injected area in an untreated mouse with RPA. The epidermis and dermis are essentially unremarkable. However, the subdermal fat is edematous and shows the margination of neutrophils along capillary walls (arrows; bottom inset) as well as neutrophilic infiltration into surrounding soft tissue. (Cii) Skin biopsy from PBS injected area in an untreated mouse with RPA. No specific pathologic changes are identified. (Ciii) Skin biopsy from anti-Ova antibody injected area in a mouse treated with 50 μg/mL CD16A-Ig before the induction of RPA. No specific pathologic changes are identified, suggesting abrogation of the Arthus reaction. (Civ) Skin biopsy from anti-Ova antibody injected area in a mouse treated with 50 μg/mL CD32A-Ig before the induction of RPA. The epidermis and dermis are essentially unremarkable. However, the subdermal fat is edematous and shows neutrophilic infiltrates in soft tissue, as well as scattered foci of leukocytoclastic vasculitis (arrows; bottom inset). Top inset: Mast cell degranulation was observed in 10 different sites 100x magnification and one of the cells is represented in the Figure inset. (D) Neutrophils were counted in 10 random sites at 63x magnifications and sum of the neutrophils were represented.

Figure 4

Histologic examination and evaluation of neutrophil infiltration in skin biopsies from anti-Ova injected areas of mice treated with or without FcγR dimers. (Ai) Skin biopsy from anti-Ova antibody–injected area in an untreated mouse with RPA (from Figure 3Ai site 3). The epidermis and dermis are essentially unremarkable. However, the subdermal fat is edematous and shows the margination of neutrophils along capillary walls (arrows; bottom inset) as well as neutrophilic infiltration into surrounding soft tissue. (Aii) Skin biopsy from PBS-injected area in an untreated mouse with RPA (from Figure 3Ai site 1). No specific pathologic changes are identified. (Aiii) Skin biopsy from anti-Ova antibody injected area in a mouse treated with 50 μg/mL CD16A-Ig before the induction of RPA (from Figure 3Avii site 3). No specific pathologic changes are identified, suggesting abrogation of the Arthus reaction. (Aiv) Skin biopsy from anti-Ova antibody injected area in a mouse treated with 50 μg/mL CD32A-Ig before the induction of RPA (from Figure 3Aii site 3). The epidermis and dermis are essentially unremarkable. However, the subdermal fat is edematous and shows neutrophilic infiltrates in soft tissue (similar to Figure 3Ai), as well as scattered foci of leukocytoclastic vasculitis (arrows; bottom inset). Top inset: Mast cell degranulation was observed in 10 different sites at 100x magnification and one of the cells is represented in the figure inset. (B) Neutrophils were counted in 10 random sites at 63x magnification and sum of the neutrophils were represented. C: To deplete the complement, mice were twice injected intraperitoneally with cobra venom factor before the initiation of RPA. The mice were injected with CD16A-Ig and CD32A-Ig intravenously (50 μg/mL of blood). After 1 hour, mice were injected intradermally with 25 μg of anti-Ova per site. (Ci) Skin biopsy from anti-Ova antibody injected area in an untreated mouse with RPA. The epidermis and dermis are essentially unremarkable. However, the subdermal fat is edematous and shows the margination of neutrophils along capillary walls (arrows; bottom inset) as well as neutrophilic infiltration into surrounding soft tissue. (Cii) Skin biopsy from PBS injected area in an untreated mouse with RPA. No specific pathologic changes are identified. (Ciii) Skin biopsy from anti-Ova antibody injected area in a mouse treated with 50 μg/mL CD16A-Ig before the induction of RPA. No specific pathologic changes are identified, suggesting abrogation of the Arthus reaction. (Civ) Skin biopsy from anti-Ova antibody injected area in a mouse treated with 50 μg/mL CD32A-Ig before the induction of RPA. The epidermis and dermis are essentially unremarkable. However, the subdermal fat is edematous and shows neutrophilic infiltrates in soft tissue, as well as scattered foci of leukocytoclastic vasculitis (arrows; bottom inset). Top inset: Mast cell degranulation was observed in 10 different sites 100x magnification and one of the cells is represented in the Figure inset. (D) Neutrophils were counted in 10 random sites at 63x magnifications and sum of the neutrophils were represented.

Close modal

Because complement peptides such as C5a are known chemoattractants of neutrophils, we have also analyzed the tissue sections of mice treated with CVF to determine the role of complement in inducing cellular infiltration in RPA. The biopsies taken from antibody-injected and PBS-injected areas of the skin of untreated, CD16A-Ig–treated, and CD32A-Ig–treated mice were subjected to histologic analysis. As seen in Figure 4C,D, the neutrophil accumulation, margination around venules, and mast cell degranulation (top insets) in the anti-Ova injected areas of untreated (Figure 4Ci), CD16A-Ig treated (Figure 4Ciii), and CD32A-Ig– treated (Figure 4Civ) mice were similar to those of mice without complement depletion (Figure 4Ai-Aiv,B). These data suggest that the interaction of IC with FcγRs expressed on the cells reside at the site of IC-formation, not the complement pathway, play a major role in induction of RPA and neutrophil emigration from the circulation. These histologic data further confirm the results obtained using dye extravasation method (Figures 2,3), and show that recombinant CD16A-Ig dimer blocks IC-induced tissue damage when administered in vivo.

We have also carried out immunohistochemistry to determine the accumulation of macrophages in RPA (Figure 5A,B). Resident macrophages were found in the PBS injected area of the skin (Figure 5Aii), while accumulation of macrophages was observed in antibody-injected area of skin in untreated mice (Figure 5Ai). The results from the dimer treated mice show that like neutrophils, the IC-induced accumulation of macrophages was also inhibited by CD16A-Ig administration (Figure 5Aiii,B). CD32A-Ig treatment did not inhibit macrophage accumulation (Figure 5Aiv). Analysis of slides from complement-depleted mice demonstrated that the accumulation of macrophages is also independent of the complement system (Figure 5C,D). Interestingly, unlike neutrophils, we did not observe margination of macrophages around venules, suggesting that most of these macrophages may have migrated from the tissues surrounding the IC injected area (data not shown). This suggests that the mechanism of accumulation of these two types of inflammatory cell populations may be distinct.

Figure 5

Immunohistochemical examination to detect the macrophages in skin biopsies from anti-Ova injected areas of mice treated with or without FcγR dimers. (A) Skin biopsies of the above mentioned sections were processed to detect the macrophages (brown cells indicated by arrow) by immunohistochemistry. (Ai) Accumulation of macrophages in anti-Ova antibody injected area of untreated mice. (Aii) Presence of resident macrophages in PBS injected area of untreated mice. (Aiii) Inhibition of macrophage accumulation in anti-Ova antibody injected area of CD16A-Ig treated mice. (Aiv) Accumulation of macrophages in anti-Ova antibody injected area of CD32A-Ig treated mice. (B) Macrophages were counted in 10 random sites at 63x magnification and the sum of the macrophages is presented. (C) Skin biopsies of the above mentioned sections from complement-depleted mice were processed to detect the macrophages (brown cells indicated by arrow) by immunohistochemistry. (Ci) Accumulation of macrophages in anti-Ova antibody injected area of untreated mice. (Cii) Presence of resident macrophages in PBS injected area of untreated mice. (Ciii) Inhibition of macrophage accumulation in anti-Ova antibody injected area of CD16A-Ig treated mice. (Civ) Accumulation of macrophages in anti-Ova antibody injected area of CD32A-Ig treated mice. (D) Macrophages were counted in 10 random sites at 63x magnification and the sum of the macrophages is presented.

Figure 5

Immunohistochemical examination to detect the macrophages in skin biopsies from anti-Ova injected areas of mice treated with or without FcγR dimers. (A) Skin biopsies of the above mentioned sections were processed to detect the macrophages (brown cells indicated by arrow) by immunohistochemistry. (Ai) Accumulation of macrophages in anti-Ova antibody injected area of untreated mice. (Aii) Presence of resident macrophages in PBS injected area of untreated mice. (Aiii) Inhibition of macrophage accumulation in anti-Ova antibody injected area of CD16A-Ig treated mice. (Aiv) Accumulation of macrophages in anti-Ova antibody injected area of CD32A-Ig treated mice. (B) Macrophages were counted in 10 random sites at 63x magnification and the sum of the macrophages is presented. (C) Skin biopsies of the above mentioned sections from complement-depleted mice were processed to detect the macrophages (brown cells indicated by arrow) by immunohistochemistry. (Ci) Accumulation of macrophages in anti-Ova antibody injected area of untreated mice. (Cii) Presence of resident macrophages in PBS injected area of untreated mice. (Ciii) Inhibition of macrophage accumulation in anti-Ova antibody injected area of CD16A-Ig treated mice. (Civ) Accumulation of macrophages in anti-Ova antibody injected area of CD32A-Ig treated mice. (D) Macrophages were counted in 10 random sites at 63x magnification and the sum of the macrophages is presented.

Close modal

CD16A-Ig binding to IC does not block the complement-mediated hemolytic activity of IgG molecule

The Fc domain of IgG IC is capable of inducing inflammation using both FcγRs and complement pathways. Although complement- and FcγR-binding sites on the Fc domain of IgG are distinct, it is a possibility that the binding of CD16A-Ig molecule to the Fc domain of IC may hinder the binding of C1q and thus prevent complement activation. To rule out whether CD16A-Ig binding altered the complement activating property of IC, we determined the hemolysis of rabbit anti-DNP IgG opsonized rRBCs by mouse serum in the presence and absence of CD16A-Ig. Because mouse complement does not lyse IgG-opsonized sheep or mouse RBCs, we used rabbit anti-DNP IgG opsonized rRBCs for these assays.41  Titration of mouse serum showed that 1:5 dilution caused 50% hemolysis of rRBC (Figure S4). At the same serum dilution, the complement-mediated hemolysis of rRBCs was unaffected by the presence of CD16A-Ig (Figure 6A). This suggests that the lack of inflammation induced by IC during CD16A-Ig administration is not due to any alteration in complement activating property of IC that might have resulted from binding of Fc domain of IgG by CD16A-Ig.

Figure 6

Effect of CD16A-Ig on complement-mediated hemolytic activity. (A) Rabbit anti-DNP-IgG opsonized rRBCs were incubated with or without various concentrations of CD16A-Ig and then 1:5 diluted mouse serum was added. Hemolytic activity was then carried out as described in the text. Cells treated with buffer alone served as a control. Cells lysed with water represented 100% hemolysis. The supernatant was read at 450nm. Data are representative of 3 independent experiments. (B) Clearance of FcγR-Ig dimers from circulation. A group of mice (n = 3) were injected with dimers and blood samples were collected at various time points and diluted in PBS/EDTA. Plasma was collected to detect the FcγR-Ig dimers by sandwich ELISA. Plates were coated with 50 μL of 10 μg/mL anti-hCD16A (CLBFcgran-1) and anti-hCD32A (IV.3) mAbs overnight at 4°C. The wells were then blocked with PBS/5mM EDTA/1% BSA. After washing, 50 μL of the plasma samples were added into the wells and incubated for another 1 hour. The wells were washed and 50 μL of HRP-conjugated anti–human Fc specific antibody were added and incubated for another 1 hour. HRP substrate was added to the washed wells and read at 450 nm. The plasma from a group of normal mice injected with PBS served as a specificity control. As positive controls, purified CD16A-Ig and CD32A-Ig were used while BSA coated wells served as negative controls. Purified CD32A-Ig was used as a standard to quantify the level of dimers in the blood. Data are means plus or minus SD of triplicates.

Figure 6

Effect of CD16A-Ig on complement-mediated hemolytic activity. (A) Rabbit anti-DNP-IgG opsonized rRBCs were incubated with or without various concentrations of CD16A-Ig and then 1:5 diluted mouse serum was added. Hemolytic activity was then carried out as described in the text. Cells treated with buffer alone served as a control. Cells lysed with water represented 100% hemolysis. The supernatant was read at 450nm. Data are representative of 3 independent experiments. (B) Clearance of FcγR-Ig dimers from circulation. A group of mice (n = 3) were injected with dimers and blood samples were collected at various time points and diluted in PBS/EDTA. Plasma was collected to detect the FcγR-Ig dimers by sandwich ELISA. Plates were coated with 50 μL of 10 μg/mL anti-hCD16A (CLBFcgran-1) and anti-hCD32A (IV.3) mAbs overnight at 4°C. The wells were then blocked with PBS/5mM EDTA/1% BSA. After washing, 50 μL of the plasma samples were added into the wells and incubated for another 1 hour. The wells were washed and 50 μL of HRP-conjugated anti–human Fc specific antibody were added and incubated for another 1 hour. HRP substrate was added to the washed wells and read at 450 nm. The plasma from a group of normal mice injected with PBS served as a specificity control. As positive controls, purified CD16A-Ig and CD32A-Ig were used while BSA coated wells served as negative controls. Purified CD32A-Ig was used as a standard to quantify the level of dimers in the blood. Data are means plus or minus SD of triplicates.

Close modal

In vivo half-life of CD16A-Ig

Analysis of the kinetics of clearance from the circulation shows that the plasma level of both the administered dimers dropped quickly (nearly 23%) until 8 hours, maintained a steady state up to 90 hours and then started declining rapidly. The reason for the sudden initial drop is not clear. It is possible that the dimers might be diffusing into extracellular space from the circulation. The FcγR-Ig dimers were detected in mouse blood up to 160 hours after their administration. The in vivo half-life in the circulation for both dimeric CD16A-Ig and CD32A-Ig was estimated to be 120 hours (Figure 6B). This suggests that it is possible to maintain a plasma concentration of the systemically administered decoy receptors high enough to block of IC-mediated inflammation for several days. The high half-life of Fc fusion proteins has been attributed to the Fc domain; the Fc domain of IgG binds to neonatal Fc receptor (FcRn), which results in protection from degradation by the endocytic machinery of the cells.42  The Fc domain that we used here to make FcγR-Ig fusion proteins has mutations that affect the FcγR binding.25,27  Because FcRn and FcγR bind to distinct sites on IgG, we do not anticipate that the mutations in the Fc domain have any effect on the FcRn binding and consequently the half-life of the mutated IgG-Fc fusion molecules.43,44 

Autoantibody-antigen IC formed in many autoimmune diseases amplify tissue damage by attracting inflammatory cells, such as neutrophils using both complement and FcγR-dependent mechanisms. Dissecting the precise roles of these two pathways in recruitment of neutrophils to the inflammatory site will lead to a better understanding of the mechanisms and treatment of the disease. We have used an experimental strategy that selectively neutralizes the FcγR-binding activity of the ICs without manipulating the expression of the FcγRs or complement receptors on the inflammatory cells. The CD16A-Ig dimer that we used competitively blocked the binding of IC to inflammatory cells in in vitro assays and blocked IC-induced inflammation in vivo at circulating concentrations as low as 25 to 50 μg/mL. Accumulation of neutrophils is a hallmark of IC-induced RPA.45  Therefore, the relative roles of complement-derived chemotactic peptides and FcγRs in recruiting neutrophils to the extravascular sites of IC formation were investigated by analyzing neutrophil infiltration in normal and dimer administered mice before or after complement depletion. The absence of neutrophil infiltration in the dimer-treated animals (Figure 4D) and the presence of neutrophil infiltration at the site of IC-formation despite the depletion of complements (Figure 4Ci) suggest that the chemotactic complement peptides are not involved in the recruitment of neutrophils to the site of IC deposition in the model system used here. A similar complement-independent but FcγR-dependent accumulation of macrophages was observed in RPA. Complement peptides such as C5a have been shown not only to recruit neutrophils via chemotaxis, but also activate mast cell degranulation. Thus, it is intriguing that complement activation that might have been triggered by IC in CD16A-Ig–administered mice did not cause mast-cell degranulation. The abrogation of mast-cell degranulation by neutralizing ICs with CD16A-Ig in the cutaneous Arthus reaction model presented here suggests that the complement activation by IC alone may not be sufficient for mast-cell degranulation. This suggests that initiation of mast-cell degranulation depends essentially on IC-FcγRs interaction but not on the complement activating property of the ICs. While this is contrary to observations made in other systems that show that mast cells degranulate in response to C5a,4,5  it is in agreement with studies using FcγR-knockout mice that show that FcγRs on mast cells are necessary for initiation of IC-induced inflammation.18,46  Activated mast cells are known to produce compounds that are chemotactic to neutrophils,6,47,48  and therefore it is possible that absence of neutrophil infiltration in the dimer-treated mice may be a consequence of lack of the mast-cell degranulation.

However, the participation of cell-derived C5a in neutrophil recruitment to inflammatory site cannot be ruled out. Recently, it has been shown20,21  that engagement of activating FcγRs up-regulated the production of cell-derived C5 and C5a, and, subsequently, C5a up-regulated the expression of activating FcγRs while down-regulating inhibitory FcγRs,21  suggesting cell-derived C5a could play a role in IC-induced inflammation by altering the level of expression of FcγRs. Thus the IC can produce the neutrophil chemoattractant C5a using two different pathways; directly by triggering classical pathway of complement activation, or indirectly by inducing production of cell-derived C5a by engaging FcγRs. The complement depletion studies described here used CVF, which blocks the three major pathways of C5a production by binding to C349,50  but not the cell-derived pathway. Therefore, although the results presented here show that complement activation pathways directly triggered by IC do not recruit neutrophils, they do not rule out the role of cell-derived C5a that are produced as a result of IC interaction with the inflammatory cells in neutrophil recruitment. At present, the relative contribution of the direct and the cell-derived pathways of complement activation in the recruitment of neutrophils are not known.

The results show that the extravasation and emigration of neutrophils that occur during the early phase of IC-induced cutaneous inflammation depend on the ability of IC to interact with FcγRs and are independent of the complement activation pathways that can be blocked by CVF. The administration of CD16A-Ig also blocked mast-cell degranulation at the inflammatory site. Based on these observations, we hypothesize that the administration of decoy CD16A-Ig dimer prevented IC from binding to mast-cell FcγRs by occupying the Fc domain of the IC (Figure 7) and consequently prevented mast cell degranulation, neutrophil recruitment, and inflammation. This is in agreement with the previous observations from FcγR knockout mice and mast cell deficient mice, which suggested that the Arthus reaction depends on FcγRs-triggered mast-cell degranulation.18,46,51  In contrast to our observations with recombinant soluble CD16A-Ig dimer presented here, an earlier study that used a recombinant soluble CD32A has concluded that parenterally administered soluble FcγRs is not a practical approach to block IC-mediated inflammation.52  Their conclusion was based on the observation that the systemically administered CD32A has a half-life of only 25 minutes and is unable to block Arthus reaction. This report also showed that soluble CD32A could block Arthus reaction only when administered locally along with the IC at a concentration of 5mg/mL. It is possible that the requirement for such a high concentration and very low in vivo half-life may be due to the monomeric nature of soluble CD32A that was used in their study. Interestingly, however, our results with CD32A-Ig dimer suggest other possibilities. We found that CD32A is not able to block the Arthus reaction in mice even after dimerization. This is not due to loss of function of CD32A after dimerization; the purified CD32A-Ig is able to competitively block binding of CHO cells expressing cell surface CD32A to IC (data not shown). Our results suggest that CD32A-Ig is not able to compete with mouse FcγRs for binding to IC either because the affinity of CD32A-Ig may be too low, or mouse FcγRs and human CD32A may be binding to distinct regions of rabbit IgG. Thus our results, although supporting the observation reported by Ireino et al52  that CD32A cannot practically block the IC-mediated inflammation, do, however, demonstrate the feasibility of using systemic administration of CD16A-Ig to block acute inflammation mediated by IC.

Figure 7

A hypothetical model depicting the action of in vivo administered CD16A-Ig in Arthus reaction. Mφ = macrophages, Nφ = neutrophils.

Figure 7

A hypothetical model depicting the action of in vivo administered CD16A-Ig in Arthus reaction. Mφ = macrophages, Nφ = neutrophils.

Close modal

In summary, our results suggest that the interaction of IC with the FcγRs expressed on cells residing in the extravascular site triggers a pathway of neutrophil recruitment that is independent of IC-induced complement activation. Our results emphasize that the engagement of FcγRs by ICs is a crucial event in initiating the inflammatory cascade. The observations reported here may be of clinical relevance. The interaction of FcγRs-bearing inflammatory immune cells with autoantigen-antibody ICs is implicated in the pathogenesis of several autoimmune diseases such as systemic lupus erythematosus, glomerulonephritis, and arthritis.15,53,,,,58  Neutrophil infiltration plays an important role in the initiation of inflammation in these autoimmune diseases. Because the inflammation and recruitment of neutrophils can be blocked by systemically administered decoy FcγR-Ig dimers, this strategy could be applied to treat antibody-mediated inflammatory and autoimmune diseases.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

The authors thank Dr Aaron Lukacher, Prof Aftab Ahmed Ansari, Dr Robert Swerlick, Seema Patel, and Saranya Selvaraj for critical reading of the manuscript, and Dr Kenneth E. Bernstein for his help in taking high-resolution mast-cell pictures.

This study was supported by a National Institutes of Health grant (RO1 AI 049400) to P.S.

National Institutes of Health

Contribution: R.S. designed, performed research, analyzed data and drafting the paper; R.A.H., S.F., P.P., T.L., and M.S., performed research and analyzed data; P.S. designed, performed research, analyzed data, and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Periasamy Selvaraj, PhD, Associate Professor, Department of Pathology, 7309 WMB, Emory University, 101 Woodruff Circle, Atlanta, GA 30322; e-mail: [email protected].

1
Centers for Disease Control
The most frequent causes of disability among Americans aged 18 years or older.
MMWR
2001
50
120
125
2
Schwartz
RS
Paul
WE
Autoimmunity and autoimmune diseases.
Fundamental Immunology
1993
New York
Raven Press, Ltd
1033
1097
3
Abbas
AK
Lichtman
AH
Pober
JS
Immune-mediated tissue injury and disease.
Cellular and Molecular Immunology
1997
Philadelphia PA
W.B. Saunders
423
438
4
Guo
RF
Ward
PA
Role of C5a in inflammatory responses.
Annu Rev Immunol
2005
23
821
852
5
Müller-Eberhard
HJ
Molecular organisation of the complement system.
Annu Rev Biochem
1988
57
321
347
6
Zhang
Y
Ramos
BF
Jakschik
BA
Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis.
Science
1992
258
1957
1959
7
Zhang
Y
Ramos
BF
Jakschik
BA
Augmentation of reverse Arthus reaction by mast cells in mice.
J Clin Invest
1991
88
841
846
8
Bozic
CR
Lu
B
Hopken
UE
Gerard
C
Gerard
NP
Neurogenic amplification of immune complex inflammation.
Science
1996
273
1722
1725
9
Sylvestre
D
Clynes
RA
Ma
M
Warren
H
Carroll
MC
Ravetch
J
Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice.
J Exp Med
1996
184
2385
2392
10
Coxon
A
Cullere
X
Knight
S
et al
FcgRIII mediates neutrophil recruitment to immune complexes: a mechanism for neutrophil accumulation in immune-mediated inflammation.
Immunity
2001
14
693
702
11
Nimmerjahn
F
Ravetch
JV
Fc gamma receptors: Old friends and new family members.
Immunity
2006
24
19
28
12
Takai
T
Fc receptors and their role in immune regulation and autoimmunity.
J Clin Immunol
2005
25
1
18
13
van Sorge
NM
van der Pol
W-L
Van de Winkel
JGJ
FcγR Polymorphisms: Implications for function, disease susceptibility and immunotherapy.
Tis Ant
2003
61
189
202
14
Hogarth
PM
Fc receptors are major mediators of antibody-based inflammation in autoimmunity.
Curr Opin Immunol
2002
14
798
802
15
Takai
T
Li
M
Sylvestre
D
Clynes
R
Ravetch
JV
FcR gamma chain deletion results in pleiotrophic effector cell defects.
Cell
1994
76
519
529
16
Ravetch
JV
Clynes
RA
Divergent roles for Fc receptors and complement in vivo.
Annu Rev Immunol
1998
16
421
432
17
Clynes
R
Dumitru
C
Ravetch
JV
Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis.
Science
1998
279
1052
1054
18
Hazenbos
WL
Gessner
JE
Hofhuis
FM
et al
Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice.
Immunity
1996
5
181
188
19
Atkinson
JP
C5a and Fc gamma Receptors: a mutual admiration society.
J Clin Invest
2006
116
304
306
20
Shushakova
N
Skokowa
J
Schulman
J
et al
C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease.
J Clin Invest
2002
110
1823
1830
21
Kumar
V
Ali
SR
Konrad
S
et al
Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice.
J Clin Invest
2006
116
512
520
22
Li
P
Nagarajan
S
Zhu
C
Selvaraj
P
Recombinant CD16A-Ig forms a homodimer and cross-blocks the ligand binding functions of neutrophil and monocyte Fcgamma receptors.
Mol Immunol
2001
38
527
538
23
Li
P
Jiang
N
Nagarajan
S
Wohlhueter
R
Selvaraj
P
Zhu
C
Affinity and kinetic analysis of Fcgamma receptor IIIa (CD16A) binding to IgG ligands.
J Biol Chem
2007
282
6210
6221
24
Rosen
H
Gordon
S
Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells recritment in vivo.
J Exp Med
1987
166
1685
1701
25
Chappel
MS
Isenman
DE
Everett
M
Xu
YY
Dorrington
KJ
Klein
MH
Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies.
Proc Natl Acad Sci U S A
1991
88
9036
9040
26
Chappel
MS
Isenman
DE
Oomen
R
Xu
YY
Klein
MH
Identification of a secondary Fc gamma RI binding site within a genetically engineered human IgG antibody.
J Biol Chem
1993
268
25124
25131
27
Ledbetter
JA
Gilliand
LK
Hayden
MS
Linsley
PS
Bajorath
J
Fell
HP
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in mammalian cells.
United States Patent
6132992
2000
28
Nagarajan
S
Chesla
SE
Cobern
L
Anderson
P
Zhu
C
Selvaraj
P
Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms.
J Biol Chem
1995
270
25762
25770
29
Nagarajan
S
Venkiteswaran
K
Anderson
M
Sayed
U
Zhu
C
Selvaraj
P
Cell specific, activation dependent regulation of neutrophil CD32A ligand binding function.
Blood
2000
95
1069
1077
30
Pricop
L
Salmon
JE
Edberg
JC
Beavis
AJ
Flow cytometric quantitation of attachment and phagocytosis in phenotypically-defined subpopulations of cells using PKH26-labeled Fc gamma R-specific probes.
J Immunol Methods
1997
205
55
65
31
Zhang
P
Guo
J
Dzhagalov
I
He
YW
An essential function for the calcium-promoted Ras inactivator in Fcgamma receptor-mediated phagocytosis.
Nat Immunol
2005
9
911
919
32
Coligan
JE
Bierer
B
Margulies
DH
et al
Coico
R
Complement.
Current Protocols in Immunology
2007
National Institutes of Health
John Wiley and Sons
13.1.1
13.1.26
33
Harkness
JE
Wagner
JE
Biology and husbandry.
The biology and medicine of rabbits and rodents
1989
Philadelphia PA
Lea and Febiger
372
385
34
Jones
DH
Looney
RJ
Anderson
CL
Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength.
J Immunol
1985
135
3348
3353
35
Arthus
M
Injections répétées de serum de cheval chez le lapin.
C R Soc Biol
1903
55
817
825
36
Sylvestre
DL
Ravetch
JV
Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade.
Science
1994
265
1095
1098
37
Ramos
BF
Zhang
Y
Jakschik
BA
Neutrophil elicitation in the reverse passive Arthus reaction complement-dependent and complement-independent mast cell involvement.
J Immunol
1994
152
1380
1390
38
Baumann
U
Chouchakova
N
Gewecke
B
et al
Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptors in IgG immune complex-induced injury of skin and lung.
J Immunol
2001
167
1022
1027
39
Baumann
U
Kohl
J
Tschernig
T
et al
A codominant role of FcgammaRI/III and C5aR in the reverse Arthus reaction.
J Immunol
2000
164
1065
1070
40
Hopken
UE
Lu
B
Gerard
NP
Gerard
C
Impaired inflammatory responses in the reverse Arthus reaction through genetic deletion of the C5a receptor.
J Exp Med
1997
185
749
756
41
Van Dijik
H
Rademaker
PM
Willers
JMN
Estimation of classical pathway of mouse complement activity by use of sensitized rabbit erythrocytes.
J Immunol Methods
1980
39
257
268
42
Junghans
RP
Anderson
CL
The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.
Proc Natl Acad Sci U S A
1996
93
5512
5516
43
Tao
MH
Morrison
SL
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
J Immunol
1989
143
2595
2601
44
Roopenian
DC
Akilesh
S
FcRn: the neonatal Fc receptor comes of age.
Nat Rev Immunol
2007
7
715
725
45
Crowford
JP
Movat
HZ
Minta
JO
Opas
M
Acute inflammation induced by immune complexes in the microcirculation.
Exp Mol Pathol
1985
42
175
193
46
Sylvestre
DL
Ravetch
JV
A dominant role for mast cell Fc receptors in the Arthus reaction.
Immunity
1996
5
387
390
47
Benoist
C
Mathis
D
Mast cells in autoimmune disease.
Nature
2002
420
875
878
48
Chen
R
Ning
G
Zhao
M
et al
Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid.
J Clin Invest
2001
108
1151
1158
49
Pepys
MB
Role of complement induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody response.
J Exp Med
1974
140
126
145
50
Szalai
AJ
Digerness
SB
Agrawal
A
et al
The Arthus reaction in rodents: species-specific requirement of complement.
J Immunol
2000
164
463
468
51
Lee
DM
Friend
DS
Gurish
MF
Benoist
C
Mathis
D
Brenner
MB
Mast cells: A cellular link between autoantibodies and inflammatory arthritis.
Science
2002
297
1689
1692
52
Ierino
FL
Powell
MS
McKenzie
IFC
Hogarth
PM
Recombinant soluble human Fc-gamma-RII: Production, characterization, and inhibition of the Arthus reaction.
J Exp Med
1993
178
1617
1628
53
Clarkson
SB
Bussel
JB
Kimberly
RP
Valinsky
JE
Nachman
RL
Unkeless
JC
Treatment of refractory immune thrombocytopenic purpura with anti-Fcγ receptor antibody.
New Engl J Med
1986
314
1236
1239
54
Ravetch
JV
Bolland
S
IgG Fc Receptors.
Annu Rev Immunol
2001
19
275
290
55
Takai
T
Nakamura
A
Akiyama
K
Fc receptors as potential targets for the treatment of allergy, autoimmune disease and cancer.
Curr Drug Targets Immune Endocr Metabol Disord
2003
3
187
197
56
Cohen-Solal
JF
Cassard
L
Fridman
WH
Sautes-Fridman
C
Fc gamma receptors.
Immunol Lett
2004
92
199
205
57
Tarzi
RM
CooK
HT
Role of Fc gamma receptors in glomerulonephritis.
Nephron Exp Nephrol
2003
95
e7
e12
58
Nakamura
A
Takai
T
A role of FcgammaRIIB in the development of collagen-induced arthritis.
Biomed Pharmacother
2004
58
292
298
59
Pricop
L
Gokhale
J
Redecha
P
Ng
SC
Salmon
JE
Reactive oxygen intermediates enhance FC gamma receptor signaling and amplify phagocytic capacity.
J Immunol
1999
162
7041
7048

Supplemental data

Sign in via your Institution